What is ROAR?

ROAR’s purpose is to supply resources, support, and understanding to those touched by addiction. With one ROAR, we can all advocate for change. 
ROAR-connection
Connection
Connecting community through educational and supportive resources, groups, and events. Please check the calendar for what is going on in your community.
Support
ROAR believes there is power and strength in numbers. ROAR is the solution for isolation and hopelessness, and will build and connect communities affected by substance abuse. 
Voice
This is a place for you to be heard. Your story matters. We must speak out NOW. To bring about change and fight this disease.
Action Network
ROAR is building a nationwide network of parents, family members, friends, and community members who are willing to stand up to advocate for real change.
together we roar
Story

Julie’s Story

We lost our son Boone to drugs in 2017. He had been using xanax recreationally for a few months under our noses, but his habit increased significantly after his close

Read More »
FDA should immediately seek removal of oral and transmucosal UHDU opioid analgesics from the market.
FDA should immediately seek removal of oral and transmucosal UHDU opioid analgesics from the market.
Opioid molecules differ in the amount required to produce an effect of given intensity, also called potency. The morphine milligram equivalent (MME) daily dose for each opioid can be calculated using a conversion factor. UHDU opioids are formulations that when taken as directed exceed 90 MME/day, a dose the Centers for Disease Control and Prevention (CDC) has determined to be dangerously high.1
An example of an extended release (ER) UHDU opioid is the OxyContin 80 milligram tablet. A patient directed to take one tablet twice a day is consuming 160 milligrams of oxycodone per day, which is equal to 240 MME/day and far greater than the CDC’s recommended 90 MME/day upper dose. Because only one pill is taken at a time, the patient and prescriber may not appreciate that this is an extremely high dose. If FDA responds to this request, it will seek removal of the OxyContin 80mg tablet.